The Priority Review

Tag

Antengene

1 story

Stories

  1. Clinical trials

    Antengene announces first patient dosed in Phase I ATTRACT study of ATG-201

    The company announced dosing began on Nov. 5, 2026 in China. The study is being conducted in China and Australia, and ATG-201 has received Human Research Ethics Committee approval in Australia and completed the Clinical Trial Notification process with the Therapeutic Goods Administration.